基本信息
浏览量:358
职业迁徙
个人简介
Practice Information:
Clinical Interest(s): Early Drug Development, Hematology, Lung Cancer, Solid Oncology
Scientific Interest(s):
Dr. Jonathan Goldman focuses on lung cancer research and early drug development.
Selected Cancer-Related Publications:
Goldman JW, Raju RN, Gordon GA, Vukovic VM, Bradley R, Rosen LS. A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors. Submitted for review.
Goldman JW, Garon EB. Targeting MEK for the treatment of non-small cell lung cancer: a review from the 12th annual targeted therapies of treatment of lung cancer. Journal of Thoracic Oncology, 2012.
Goldman JW, Laux I, Chai F, Savage RE, Ferrari D, Garmey EG, Just RG, Rosen LS. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer. 2012 Dec 1;118(23):5903-11. doi: 10.1002/cncr.27575. Epub 2012 May 17.
Ralli M, Goldman JW, Lee E, Pinter-Brown LC, Glasgow BJ, Sarraf D. Intraocular involvement of mycosis fungoides. Arch Ophthalmol. 2009 Mar;127(3):343-5.
O'Connor PM, Nieves-Neira W, Kerrigan D, Bertrand R, Goldman J, Kohn KW, Pommier Y. S-phase population analysis does not correlate with the cytotoxicity of camptothecin and 10,11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells. Cancer Commun. 1991 Aug;3(8):233-40.
Clinical Interest(s): Early Drug Development, Hematology, Lung Cancer, Solid Oncology
Scientific Interest(s):
Dr. Jonathan Goldman focuses on lung cancer research and early drug development.
Selected Cancer-Related Publications:
Goldman JW, Raju RN, Gordon GA, Vukovic VM, Bradley R, Rosen LS. A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered once weekly in patients with solid tumors. Submitted for review.
Goldman JW, Garon EB. Targeting MEK for the treatment of non-small cell lung cancer: a review from the 12th annual targeted therapies of treatment of lung cancer. Journal of Thoracic Oncology, 2012.
Goldman JW, Laux I, Chai F, Savage RE, Ferrari D, Garmey EG, Just RG, Rosen LS. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer. 2012 Dec 1;118(23):5903-11. doi: 10.1002/cncr.27575. Epub 2012 May 17.
Ralli M, Goldman JW, Lee E, Pinter-Brown LC, Glasgow BJ, Sarraf D. Intraocular involvement of mycosis fungoides. Arch Ophthalmol. 2009 Mar;127(3):343-5.
O'Connor PM, Nieves-Neira W, Kerrigan D, Bertrand R, Goldman J, Kohn KW, Pommier Y. S-phase population analysis does not correlate with the cytotoxicity of camptothecin and 10,11-methylenedioxycamptothecin in human colon carcinoma HT-29 cells. Cancer Commun. 1991 Aug;3(8):233-40.
研究兴趣
论文共 405 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Targeted Oncologyno. 2 (2024): 1-4
Claire F. Friedman, Anishka D'Souza, Diana Bello Roufai,Anna Tinker, Maria de Miguel, Valentina Gambardella,Jonathan Goldman,Sherene Loi,Michelle E. Melisko,Ana Oaknin,Iben Spanggaard,Geoffrey I. Shapiro,
GYNECOLOGIC ONCOLOGY (2024): 162-169
Cancer Researchno. 7_Supplement (2024)
Amy R. Rappaport,Chrisann Kyi, Monica Lane, Meghan G. Hart,Melissa L. Johnson,Brian S. Henick,Chih-Yi Liao,Amit Mahipal,Ardaman Shergill, Alexander I. Spira,Jonathan W. Goldman, Ciaran D. Scallan,
Nature Medicineno. 4 (2024): 1-10
Clinical cancer research : an official journal of the American Association for Cancer Researchno. 4 (2024): 824-835
JAMA ONCOLOGYno. 3 (2024): 352-359
Gregory J. Riely,Egbert F. Smit,Myung-Ju Ahn,Enriqueta Felip,Suresh S. Ramalingam,Anne Tsao,Melissa Johnson,Francesco Gelsomino, Raymond Esper,Ernest Nadal,Michael Offin,Mariano Provencio,
FUTURE ONCOLOGY (2024)
Jonathan W Goldman,Lynette M Sholl,Sanja Dacic, Michael C Fishbein,Yonina R Murciano-Goroff,Ravi Rajaram, Sylwia Szymczak, Anna M Szpurka,Bo H Chao,Alexander Drilon
Frontiers in oncology (2023): 1178313
Journal of clinical oncology : official journal of the American Society of Clinical Oncologyno. 21 (2023): 3700-+
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn